No Panacea for Merck?

New CEO Richard Clark draws few cheers on the Street, where he is seen as unlikely to administer the sort of tough medicine that many think the drugmaker needs

By Amy Barrett

To continue reading this article you must be a Bloomberg Professional Service Subscriber.